Aprea Therapeutics Files 8-K on Financial Condition

TL;DR

**Aprea Therapeutics just dropped an 8-K on its financial results, signaling a key update for investors.**

AI Summary

Aprea Therapeutics, Inc. filed an 8-K on February 2, 2024, to report on its 'Results of Operations and Financial Condition.' This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is managing its finances and operating its business, directly impacting the stock's perceived value and potential future movements.

Why It Matters

This filing provides an update on Aprea Therapeutics' financial health, which is essential for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying 'Results of Operations and Financial Condition' could contain positive or negative news, creating medium risk.

Analyst Insight

Investors should await the full details of the 'Results of Operations and Financial Condition' to understand the financial implications for Aprea Therapeutics, Inc. and then decide on their investment strategy.

Key Players & Entities

• Aprea Therapeutics, Inc. (company) — the registrant filing the 8-K
• February 2, 2024 (date) — date of report and earliest event reported
• 001-39069 (other) — Commission File Number
• APRE (other) — Trading Symbol on The Nasdaq Stock Market LLC
• $0.001 (dollar_amount) — par value per share of common stock

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
• $21.6 million — cts to report that it had approximately $21.6 million of cash, cash equivalents, and restrict

Filing Documents

• tm244107d6_8k.htm (8-K) — 26KB
• 0001104659-24-010057.txt ( ) — 195KB
• apre-20240202.xsd (EX-101.SCH) — 3KB
• apre-20240202_lab.xml (EX-101.LAB) — 33KB
• apre-20240202_pre.xml (EX-101.PRE) — 22KB
• tm244107d6_8k_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Based upon preliminary and unaudited estimates and information available to Aprea Therapeutics, Inc. (the "Company") as of the date of this report, the Company expects to report that it had approximately $21.6 million of cash, cash equivalents, and restricted cash as of December 31, 2023. The Company has not yet completed its year-end financial close process for the fiscal year ended December 31, 2023. This estimate of the Company's cash, cash equivalents, and restricted cash for the fiscal year ended December 31, 2023, is preliminary, has not been audited and is subject to change upon completion of the Company's financial financial position and results of operations as of December 31, 2023. The Company's independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: February 2, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR